Sterling Financial Planning Inc. Boosts Stock Position in Johnson & Johnson (NYSE:JNJ)

Sterling Financial Planning Inc. boosted its holdings in Johnson & Johnson (NYSE:JNJGet Rating) by 24.3% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 12,945 shares of the company’s stock after buying an additional 2,530 shares during the quarter. Johnson & Johnson makes up about 1.4% of Sterling Financial Planning Inc.’s holdings, making the stock its 22nd largest position. Sterling Financial Planning Inc.’s holdings in Johnson & Johnson were worth $2,215,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. Capital Investment Counsel Inc boosted its position in shares of Johnson & Johnson by 0.8% in the 4th quarter. Capital Investment Counsel Inc now owns 7,796 shares of the company’s stock worth $1,334,000 after purchasing an additional 59 shares in the last quarter. Iron Horse Wealth Management LLC grew its position in shares of Johnson & Johnson by 29.9% in the 4th quarter. Iron Horse Wealth Management LLC now owns 265 shares of the company’s stock worth $45,000 after buying an additional 61 shares during the last quarter. Innovative Portfolios lifted its stake in Johnson & Johnson by 3.6% during the 3rd quarter. Innovative Portfolios now owns 1,793 shares of the company’s stock valued at $290,000 after acquiring an additional 62 shares during the period. Charter Oak Capital Management LLC increased its holdings in Johnson & Johnson by 0.4% in the 3rd quarter. Charter Oak Capital Management LLC now owns 17,118 shares of the company’s stock worth $2,765,000 after acquiring an additional 63 shares in the last quarter. Finally, Magnus Financial Group LLC grew its holdings in shares of Johnson & Johnson by 0.8% during the third quarter. Magnus Financial Group LLC now owns 8,074 shares of the company’s stock worth $1,304,000 after buying an additional 63 shares in the last quarter. 67.84% of the stock is currently owned by institutional investors.

JNJ has been the topic of a number of recent research reports. StockNews.com initiated coverage on shares of Johnson & Johnson in a research note on Thursday, March 31st. They set a “strong-buy” rating on the stock. Bank of America began coverage on shares of Johnson & Johnson in a research note on Wednesday, March 2nd. They issued a “neutral” rating on the stock. The Goldman Sachs Group began coverage on shares of Johnson & Johnson in a research note on Friday, December 17th. They issued a “neutral” rating and a $161.00 price target on the stock. Morgan Stanley dropped their price target on shares of Johnson & Johnson from $175.00 to $173.00 and set an “equal weight” rating on the stock in a research note on Wednesday, April 6th. Finally, Citigroup reiterated a “buy” rating and issued a $195.00 price target (up from $192.00) on shares of Johnson & Johnson in a research note on Wednesday, December 15th. Four research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Johnson & Johnson has an average rating of “Buy” and an average target price of $180.29.

In other Johnson & Johnson news, VP Thibaut Mongon sold 23,681 shares of the firm’s stock in a transaction on Thursday, March 17th. The stock was sold at an average price of $176.25, for a total value of $4,173,776.25. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 0.35% of the stock is currently owned by company insiders.

Shares of NYSE JNJ opened at $182.12 on Monday. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.35 and a quick ratio of 1.12. The stock has a fifty day moving average price of $171.55 and a 200 day moving average price of $167.30. Johnson & Johnson has a 1-year low of $155.72 and a 1-year high of $183.19. The company has a market cap of $478.84 billion, a PE ratio of 23.32, a P/E/G ratio of 2.74 and a beta of 0.72.

Johnson & Johnson (NYSE:JNJGet Rating) last issued its quarterly earnings results on Tuesday, January 25th. The company reported $2.13 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.12 by $0.01. Johnson & Johnson had a return on equity of 37.46% and a net margin of 22.26%. The firm had revenue of $24.80 billion during the quarter, compared to the consensus estimate of $25.29 billion. During the same period last year, the company earned $1.86 earnings per share. The company’s revenue for the quarter was up 10.4% on a year-over-year basis. Analysts anticipate that Johnson & Johnson will post 10.49 earnings per share for the current fiscal year.

Johnson & Johnson Company Profile (Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.

Featured Stories

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.